World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
44
Citations
39092
World Ranking
4733
National Ranking
307

Jon M. Wigginton publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jon M. Wigginton sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 145 publications — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jon M. Wigginton D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jon M. Wigginton sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 44 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Jon M. Wigginton is affiliated with Bristol-Myers Squibb in Germany. Their primary research focus lies within the field of medicine, with significant contributions to oncology and immunology. Subfields of study in their work also include general health professions, pulmonary and respiratory medicine, and radiology, nuclear medicine, and imaging.

The scientist's work covers a range of topics primarily centered on cancer immunotherapy and related biomarker research. Key themes in their research include immunotherapy and immune responses, CAR-T cell therapy research, and the management and outcomes of gastric cancer. Additional areas of interest involve esophageal cancer research and treatment, gastrointestinal tumor research and treatment, as well as clinical research related to COVID-19.

Frequent publication venues for Jon M. Wigginton include:

  • Journal of Clinical Oncology
  • Immuno Oncology Insights
  • Value in Health
  • The Lancet Oncology
  • Journal for ImmunoTherapy of Cancer

Some of their recent published papers are:

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023, Journal of Clinical Oncology)
  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial (2020, The Lancet Oncology)
  • The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response (2020, Journal for ImmunoTherapy of Cancer)
  • Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20) (2021, Journal of Clinical Oncology)
  • A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021, Journal of Experimental & Clinical Cancer Research)

Jon M. Wigginton has collaborated frequently with several coauthors, including:

  • Drew M. Pardoll
  • Daniel V.T. Catenacci
  • Yoon-Koo Kang
  • Minori Koshiji Rosales
  • Fernanda I. Arnaldez

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • METHOD OF TREATING CANCER USING AN ANTI-PD-1 AND ANTI-CTLA-4 ANTIBODY COMBINATION

    Cogswell John P;Goldberg Stacie M;Gupta Ashok K;Jure-Kunkel Maria

  • Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

    David F. McDermott;Charles G. Drake;Mario Sznol;Toni K. Choueiri

  • Combination immunotherapy: a road map

    Patrick A. Ott;F. Stephen Hodi;Howard L. Kaufman;Jon M. Wigginton

  • The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.

    Jeffrey E Green;Masa-Aki Shibata;Katsuhide Yoshidome;Min-ling Liu

  • Immunotherapy of cancer by IL-12-based cytokine combinations.

    Jonathan M Weiss;Jeff J Subleski;Jon M Wigginton;Robert H Wiltrout

  • Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

    Sacha Gnjatic;Vincenzo Bronte;Laura Rosa Brunet;Marcus O. Butler

  • IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells

    Rosalba Salcedo;Jimmy K. Stauffer;Erin Lincoln;Timothy C. Back

  • Biology of childhood osteogenic sarcoma and potential targets for therapeutic development : Meeting summary

    Richard Gorlick;Peter Anderson;Irene Andrulis;Carola Arndt

  • Administration of Interleukin 12 With Pulse Interleukin 2 and the Rapid and Complete Eradication of Murine Renal Carcinoma

    Jon M. Wigginton;Kristin L. Komschlies;Timothy C. Back;José L. Franco

  • Defining the critical hurdles in cancer immunotherapy

    Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal

  • IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy

    Jon M. Wigginton;Eilene Gruys;Lisa Geiselhart;Jeffrey Subleski

  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

    Daniel V T Catenacci;Yoon-Koo Kang;Haeseong Park;Hope E Uronis

  • Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

    Ilia N. Buhtoiarov;Paul M. Sondel;Jon M. Wigginton;Tatiana N. Buhtoiarova

  • Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow

    Rosalba Salcedo;Julie A. Hixon;Jimmy K. Stauffer;Rashmi Jalah

  • Antitumor activity of interleukin 12 in preclinical models

    M. J. Brunda;Leopoldo Luistro;Leonid Rumennik;Rosemary B. Wright

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Unknown

  • Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses

    William J. Murphy;Lisbeth Welniak;Timothy Back;Julie Hixon

Frequent Co-Authors

Robert H. Wiltrout
Robert H. Wiltrout National Institutes of Health
Mario Sznol
Mario Sznol Yale University
Ezio Bonvini
Ezio Bonvini Center for Biologics Evaluation and Research
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
Michael B. Atkins
Michael B. Atkins Georgetown University
Charles G. Drake
Charles G. Drake Columbia University
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Thomas J. Sayers
Thomas J. Sayers Leidos (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with healthcare fields, making nursing a popular adjacent path. For those without a nursing background, there are accessible options such as online absn programs for non nurses that provide a streamlined route into nursing. These programs help build foundational skills quickly, ideal for career changers.

When selecting an accelerated nursing program, many students prioritize entry ease. Programs highlighted under absn programs with high acceptance rates offer greater accessibility, reducing barriers for eager learners aiming to enter the field promptly.

Licensed Practical Nurse (LPN) programs are another viable option for entering healthcare and can serve as stepping stones towards advanced immunology-related studies. Those looking for straightforward enrollment can explore lpn programs easy to get into, which focus on foundational nursing care essential to many medical environments.

Finally, for those pursuing advanced clinical roles, understanding what is the easiest np program is crucial. Nurse practitioner degrees with accessible admission criteria can lead to specialized roles that complement immunology research and patient care.

Best Scientists Citing Jon M. Wigginton

Trending Scientists

Recently Published Articles